entertainment -WSS

entertainment

author：explore 2025-09-27 19:38:22 - browse：5493

Palm Drive at Stanford University on March 28, 2023 — Palm Drive at the entrance to Stanford University. Brian Frank for STAT

The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities in his past research marks more than just the startling downfall of the leader of one of the nation’s top research powerhouses. The case is likely to have broader repercussions, signaling a tipping point in an ongoing and often contentious debate about how to assign blame and credit in the increasingly collaborative world of research.

Science is a team sport. And while the lab leaders, or principal investigators, often get most of the attention for biomedical breakthroughs, they seldom run experiments. That work is left to postdoctoral researchers, graduate students, and others who peer through microscopes, labor away in mouse rooms, and spend countless hours pipetting. Instead, professors play more of a managerial role, supervising, critiquing, and offering big-picture feedback on the work that goes on in their lab.

It’s a longstanding arrangement, but one that leads to a thorny question when research is challenged: Who’s to blame? STAT put that question to Stanford faculty and students while reporting earlier this year on allegations of image manipulation and other misconduct related to research in Tessier-Lavigne’s lab, as well as researchers at other institutions. The answer varied depending on whom you asked.

Graduate students stressed that since faculty have no qualms using work done in their labs to land grants, win prizes, and build prestige, they should ultimately be accountable for problems with the science done under their supervision. Faculty generally agree, at least in principle, but are often quick to say that there are limits to how closely they can scrutinize their lab’s work, and that team science is in part based on trust. It’s an argument Tessier-Lavigne cited in his own statement about his resignation.

It’s also one he said wasn’t good enough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Despite FDA concern, risk that CAR

explore

Wikipedia

WSS

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Cigna, Humana reportedly in talks to merge

Pediatric cancer treatments threatened by a new FDA policy

What to do when lifesaving products contribute to climate change

Will the market for weight loss drugs really reach $100 billion?

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

explore

entertainment

focus

The cancer drug shortage isn’t new — and neither are the solutions

Mayo Clinic plans $5B tech

Hepatitis C has a cure — but many Americans still lack access to it

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

23andMe had bad news about my health. I wish a person had delivered it

Cigna, Humana reportedly in talks to merge

Hepatitis C has a cure — but many Americans still lack access to it

Living organ donors deserve priority status for transplants

Medicare proposal to cover medical devices draws a mixed reaction

Biden administration plans revamp of organ transplant system

leisure time

Disappointing trial forces Pfizer to pivot on obesity medicine plans

How to fix the rural physician shortage in the U.S.

How to fix the rural physician shortage in the U.S.

As biotech industry slumps, bioscience job market is upside down

Despite FDA concern, risk that CAR

Eli Lilly’s Mounjaro succeeds in second weight

explore

leisure time

Wikipedia

focus